A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of ...
2dOpinion
The therapy for the future
Explore the potential of gene therapy as a groundbreaking approach to curing diseases, beyond traditional pharmacological ...
With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...
SHANGHAI and SANTA BARBARA, Calif., /PRNewswire/ -- Rona Therapeutics, a global leader in next-generation RNAi medicines, ...
Vial, a clinical-stage biotech company, today announced growing enthusiasm among metabolic disease KOLs for Vial's INHBE ...
As of Monday, December 29, Aligos Therapeutics, Inc.’s ALGS share price has dipped by 5.24%, which has investors questioning ...
Rona Therapeutics, a clinical-stage RNAi company, today announced the recent completion of Cohort 1 dosing in its Phase 1 ...
4d
Waliigaltee Ameerikaan Itoophiyaa dabalatee kaan waliin mallatteessisaa jirtu maaliif falmii kaase?
Ministeerri Fayyaa Itoophiyaa damee fayyaa biyyattii jabeessuuf mootummaa Ameerika waliin waliigaltee deeggarsaa doolaara ...
With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...
PeptiDream (TSE:4587) just logged two meaningful scientific wins, advancing an oral dual IL 17 program into its clinical portfolio and hitting a preclinical siRNA delivery milestone with Alnylam, ...
Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) ...
Hawaasa Afrikaa Kibbaa Afrikaanars Tiraamp ofitti fudhachuu fedhan maaltu kakaase? 'BBC Africa Eye' qorateera.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback